Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental hematology"
DOI: 10.1016/j.exphem.2021.07.005
Abstract: Primary refractory acute myeloid leukemia (AML) is unresponsive to conventional chemotherapy and has a poor prognosis. Despite the recent identification of novel driver mutations and advances in the understanding of the molecular pathogenesis, little is… read more here.
Keywords: chemotherapy; chemotherapy resistance; primary refractory; contribute chemotherapy ... See more keywords